Crossmark Global Holdings Inc. Acquires 18,462 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Crossmark Global Holdings increased its stake in Bristol Myers Squibb by 8.1% in Q3, buying 18,462 shares to hold 246,488 shares worth about $11.12 million.
• BMY missed on Q4 EPS ($1.26 vs. $1.65 consensus) and set FY2026 guidance of $6.05–6.35, below some analyst forecasts, a combination that helped drive a roughly 2.6% share decline.
• Reblozyl showed positive Phase 2 results and has topped roughly $2.3B in annualized sales, yet analyst coverage is mixed—consensus is a "Hold" with an average price target near $60.71 despite several recent upgrades.

Crossmark Global Holdings Inc. grew its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 8.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 246,488 shares of the biopharmaceutical company's stock after buying an additional 18,462 shares during the quarter. Crossmark Global Holdings Inc.'s holdings in Bristol Myers Squibb were worth $11,117,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb during the second quarter valued at approximately $25,000. Harbor Capital Advisors Inc. increased its stake in shares of Bristol Myers Squibb by 107.2% in the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 313 shares during the period. Total Investment Management Inc. bought a new stake in Bristol Myers Squibb during the 2nd quarter valued at $38,000. Twin Peaks Wealth Advisors LLC purchased a new stake in Bristol Myers Squibb during the 2nd quarter valued at $40,000. Finally, Mark Sheptoff Financial Planning LLC grew its holdings in Bristol Myers Squibb by 233.3% in the 2nd quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $46,000 after acquiring an additional 700 shares during the last quarter. Institutional investors own 76.41% of the company's stock.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Top-line Phase 2 results for Reblozyl in alpha‑thalassemia came back positive (primary and key secondary endpoints met; safety consistent with prior data), which strengthens BMY's late‑stage pipeline optionality and potential label expansion. Reblozyl Phase 2 Success Shapes Bristol Myers Squibb Valuation Story
• Positive Sentiment: Commercial momentum: Reblozyl has topped roughly $2.3B in annualized sales and company commentary plus an AI collaboration (Evinova) to speed trial execution underline both near‑term revenue support and improved R&D efficiency. These items support BMY’s top‑line outlook if label/drug expansion continues. Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline? Bristol Myers Squibb Adds Reblozyl Data And AI To Pipeline Story
• Neutral Sentiment: Round‑up/earnings coverage: BMY appears in lists of Q4 “outperformers” for branded pharma on revenue strength, but underlying EPS dynamics were mixed—investors should read the details rather than rely on headlines. Q4 Earnings Outperformers: Bristol-Myers Squibb NYSE: BMY And The Rest Of The Branded Pharmaceuticals Stocks
• Neutral Sentiment: Industry context: Strength at peers (e.g., Merck’s Keytruda momentum) highlights competitive dynamics in oncology that influence investor expectations for BMY’s oncology franchises. Merck's Keytruda Drives its 2025 Revenue Surge: What's Ahead?
• Neutral Sentiment: Macro/sector themes such as nanomedicine and dividend‑income positioning appeared in recent coverage; these are background drivers but less directly tied to BMY’s immediate price move. Global Nanomedicine Market is Projected Cross
• Negative Sentiment: Market reaction and fundamentals: several news pieces note BMY’s intraday/close decline (broader selling). The core negative catalysts are the Q4 EPS miss (reported EPS below consensus) and FY‑2026 guidance that sits below some analyst forecasts — these credit‑and‑earnings concerns explain why the stock is down despite pipeline positives. Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Leerink Partners increased their target price on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an "outperform" rating in a report on Tuesday, January 13th. UBS Group upgraded Bristol Myers Squibb from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $46.00 to $65.00 in a report on Wednesday, January 7th. Wells Fargo & Company reissued an "outperform" rating and set a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Barclays initiated coverage on Bristol Myers Squibb in a research note on Thursday, February 19th. They issued an "overweight" rating and a $75.00 price target for the company. Finally, Scotiabank reissued a "sector perform" rating and set a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a research report on Friday, January 9th. Nine analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of "Hold" and an average price target of $60.71.

Bristol Myers Squibb Trading Down 2.6%

NYSE BMY opened at $60.69 on Friday. The firm has a market capitalization of $123.59 billion, a PE ratio of 17.59, a P/E/G ratio of 0.18 and a beta of 0.26. The stock's 50 day moving average is $57.55 and its 200 day moving average is $50.91. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $63.33. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to analysts' expectations of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business's quarterly revenue was up 1.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were issued a dividend of $0.63 per share. The ex-dividend date was Friday, January 2nd. This is a positive change from Bristol Myers Squibb's previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. Bristol Myers Squibb's dividend payout ratio (DPR) is 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.